Zerbor/iStock via Getty Images Shares of ADMA Biologics ( NASDAQ: ADMA ) shot up 21% in post-market trading Thursday after the company raised its financial guidance and released a Q2 earnings report that topped estimates. For fiscal 2024 and 2025, ADMA now sees reporting revenue of more than $400M to $445M, up from its prior guidance of more than $355M to $410M, according to a statement. ADMA also raised its earnings forecast.
The company now sees fiscal 2024 GAAP net income of more than $105M and adjusted EBITDA of more than $150M. For fiscal 2025, ADMA is now expecting GAAP net income of more than $155M and adjusted EBITDA of more than $200M. Analysts, on average, had been expecting 2024 revenue of $357.
5M and 2025 revenue of $415.3M. ADMA released the updated guidance along with its Q2 earnings report , which also topped estimates.
More on ADMA Biologics ADMA Biologics: A Compelling GARP Stock For Biotech Investors Giving ADMA Biologics A Well-Deserved 'Booyah' ADMA Biologics GAAP EPS of $0.13 beats by $0.05, revenue of $107.
19M beats by $20.78M ADMA Biologics Q2 2024 Earnings Preview Seeking Alpha’s Quant Rating on ADMA Biologics.
